General Information
Pfizer Obesity-DM2 C3991004
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Dose Finding, Parallel Group Study to Assess Efficacy and Safety of PF-07081532, and Open Label Oral Semaglutide, in Adults with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin, and Separately PF-07081532 Compared to Matching Placebo in Adults with Obesity but Without T2DM
| Protocol | C3991004 |
|---|---|
| Identifier | |
| UID | 690ee980-1a6d-4189-99c9-2c259833b90e |
| Status | Done - Archived |
| Phase | 2 |
| Category | Obesity / Adult |
| Launch Year | 2022 |
| NCT Number | - |
| Created | 2022-09-02 13:25 |
| Last Updated | 2024-01-22 22:05 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2023-02-24 | No |
| Enrollment Open | 2022-12-19 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2022-12-14 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2023-10-27 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Casaclang, Cecilia | CCasaclang | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Pfizer |
|---|---|
| Division | Pfizer |
| Team | Pfizer |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Parexel International |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
